BioXcel Therapeutics (FRA:BX2) Other Net Income (Loss) : €0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Other Net Income (Loss)?

BioXcel Therapeutics's Other Net Income (Loss) for the three months ended in Sep. 2024 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

BioXcel Therapeutics's annual Other Net Income (Loss) declined from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then stayed the same from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

BioXcel Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for BioXcel Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Other Net Income (Loss) Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

BioXcel Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

BioXcel Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

BioXcel Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

BTAI:USA

Address

555 Long Wharf Drive, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics Headlines

No Headlines